Cardiovascular events after clopidogrel discontinuation

Reviews in Cardiovascular Medicine

Volumn 9, Issue 3, 2008, Pages 212-214

  Cannon, Christopher P ^a   Acharjee, Subroto ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HEPARIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOVASCULAR EFFECT; COMORBIDITY; DRUG WITHDRAWAL; HEART DEATH; HUMAN; INCIDENCE; NOTE; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 53949087609     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. Anderson JL, Adams CD, Antman EM, et al for the American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACCJAHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157.
2. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361-2367.
3. Becker RC, Spencer FA, Li Y, et al. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential. J Am Coll Cardiol. 1999;34:1020-1027.
4. Ross PJ, Lewis MJ, Sheridan DJ, et al. Adrenergic hypersensitivity after betablocker withdrawal. Br Heart J. 1981;45:637-642.
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Ctopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes. 2006;55:780-784.
6. McLachlan CS, Tay SK, Almsherqi Z, et al. Atherothromboric events and clopidogrel therapy. CAMJ. 2007;176:349.
7. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299:532-539.
8. Steinhubl SR, Berger PB, Mann JT 3rd, et al for the CREDO Investigators, clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAIA. 2002;288:2411-2420.
9. Rao SV, Shaw RE, Brindis RG, et al. American College of Cardiology National Cardiovascular Data Registry. On-versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol. 2006;97:1478-1481.
10. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.
11. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-168.
12. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
13. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: (2007 Writing Group to Review New Evidence and Update the 2005 Guideline Update for Percutaneous Coronary Intervention). Circulation. 2008;117:261-295.